RIG
40
-3
CCL
33
2
SYF
64
6
CMA
42
2
CHD
59
-2
PPL
52
2
GM
60
11
NOV
57
2
CSX
43
2
XYL
49
4
ETR
65
4
NWS
58
-4
QRVO
54
-9
PAYX
41
-4
DG
32
2
ABBV
42
2
WAT
44
-4
OI
50
4
MPC
49
-6
MAS
58
-10
RIG
40
-3
CCL
33
2
SYF
64
6
CMA
42
2
CHD
59
-2
PPL
52
2
GM
60
11
NOV
57
2
CSX
43
2
XYL
49
4
ETR
65
4
NWS
58
-4
QRVO
54
-9
PAYX
41
-4
DG
32
2
ABBV
42
2
WAT
44
-4
OI
50
4
MPC
49
-6
MAS
58
-10
Financhill
Back

Merrimack Pharmaceuticals Quote, Financials, Valuation and Earnings

NOW is the time to get in on this trillion-dollar megatrend

Get it here.
Sell
49

MACK
Merrimack Pharmaceuticals

Last Price:
14.73
Seasonality Move:
-8.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Unlock the Secret to Earning Monthly Income!

Limited spots act swiftly

Merrimack Pharmaceuticals Price Quote

$14.73
+0.05 (+0.34%)
(Updated: April 19, 2024 at 6:55 PM ET)

Merrimack Pharmaceuticals Key Stats

Sell
49
Merrimack Pharmaceuticals (MACK) is a Sell
Day range:
$14.67 - $14.71
52-week range:
$11.53 - $15.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
209,909.32
P/B ratio:
11.38%
Volume:
91.1K
Avg. volume:
119.2K
1-year change:
16.42%
Market cap:
$213.3M
Revenue:
$0
EPS:
$-0.08

How Much Does Merrimack Pharmaceuticals Make?

Data Unavailable

Is Merrimack Pharmaceuticals Growing As A Company?

Data Unavailable

Merrimack Pharmaceuticals Stock Price Performance

What Is Merrimack Pharmaceuticals 52-Week High & Low?

Merrimack Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Merrimack Pharmaceuticals?

Is Merrimack Pharmaceuticals Cash Flow Positive?

  • What Is MACK Cash Flow From Operations?
    Cash flow from operations (TTM) is -$1.5M
  • What Is Merrimack Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $521K
  • What Is Merrimack Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$12.4M

Merrimack Pharmaceuticals Return On Invested Capital

Data Unavailable

Merrimack Pharmaceuticals Earnings Date & Stock Price

Merrimack Pharmaceuticals Competitors

Merrimack Pharmaceuticals Dividend Yield

Data Unavailable

Merrimack Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 17.86%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

  • How many MACK shares are owned by institutional investors?
    13.6M MACK shares are owned by institutional investors
  • How many MACK shares are owned by insiders?
    5.3M MACK shares are owned by insiders